肺分支动脉留置导管内生物制剂灌注治疗晚期肺癌

探讨ＩＬ－２／ＬＡＫ细胞在介入式局部应用中的抗肿瘤作用，寻求疗铲确切，操作可行的晚期肺癌生物治疗的应用途径。我们对６０例晚期肺癌随机分为治疗组对照１组和对照２组，治疗组采用经皮颈外静脉穿刺肺分支动脉插管留置，ＩＬ－２，ＬＡＫ细胞及化疗药物联合滴注治疗；

Late Stage Lung Cancer Treated by Percutaneous Branched Pulmonary Artery Catheter Injected with Biological Preparations

In this article, we discussed anti-tumor effect of Interleukin- I (IL-2) and Lymphokin - activated Killer (LAK) cells, as in local percutaneous irans-catheter intervention application , and intended to seek an application of biotherapy, of which having both definate therapeutic effect and feasible manipulation in late stage lung cancer. Altogether 60 cases of late stage lung cancer, randomized into 3 groups. In therapeutic group, we did percutaneous branched pulmonary artery catheter through external jugular artery, with IL - 2,LAK cells and other chemotherapy drugs injected into in combination. In controled group 2, we gave only the same chemotherapy through peripheral vein. The effective rates (CR-f-PR) were-.therapeutic group 53. 5% ,controlled group 1 39. 8% and controlled group 2 33. 3%. It had been shown that: 1. when IL -2 and LAK calls and other chemotherapy drugs were used in combination . there would be a synergistic action of anti-tumor effect. 2. the local percutaneous trans-catheter intervention application of IL - 2 and LAK cells made up for their short half-time in human body, and made it possible for target tumor tissue acquiring higher dosage of immunological cells, thus help promote their anti-tumor effect.